F8 and hemophilia A: Emicizumab—a bispecific antibody that replaces the function of missing activated FVIII thereby restoring hemostasis—is a novel, non‐factor treatment for hemophilia A.11Emicizumab received licensing approval for treatment of hemophilia A with or without inhibitors in Japan in 2018.